The Biotechnology Innovation Organization took offense with the US FDA's suggestion that sponsors are exploiting a "loophole" in the Orphan Drug Act to gain an exemption from pediatric studies that otherwise would be mandated.
In comments to recent draft guidance stating that FDA would limit orphan designations in those situations, BIO argues that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?